Anti-Eculizumab Neutralizing Antibody ELISA kit

Catalog No.

KAB90002

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

15.625-1,000 ng/ml

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

5G1.1,h5G1.1HuG2/G4, CAS: 219685-50-4

Macrophage activation syndrome successfully treated with eculizumab and emapalumab: a case report., PMID:40196116

Rational design of antibody-like peptides for targeting the human complement fragment protein C5a., PMID:37933678

COVID-19 therapy and vaccination: a clinical narrative review., PMID:36793450

A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects., PMID:35348111

TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE., PMID:35282492

Current treatment in COVID-19 disease: a rapid review., PMID:33569082

[Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy]., PMID:33346448

COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking., PMID:32569708

Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy., PMID:32447592

A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris® ) in healthy male subjects., PMID:32196749

Staphylococcus aureus-induced complement activation promotes tissue factor-mediated coagulation., PMID:29437288

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases., PMID:28439081

Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria., PMID:26690023

The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load., PMID:25907631

Inhibiting the C5-C5a receptor axis., PMID:21549429

Document Download

Anti-Eculizumab Neutralizing Antibody ELISA kit.pdf